Wockhardt receives import alert from USFDA for its Ankleshwar plant

08 Aug 2016 Evaluate

Wockhardt has been issued an import alert from the US Food and Drugs Administration (USFDA) for its Ankleshwar plant for alleged violation of good manufacturing practices. This is the drug maker’s third plant to receive an import alert from the US drug regulator. The Ankleshwar unit manufactures active pharmaceutical ingredients (APIs) and was inspected last year by the US regulator.

The move is a setback to the company’s plans to revive its US business. The share of the firm’s US business in the total sales dropped to 22 percent in FY16 from 24 percent a year ago because of import restrictions. The Ankleshwar plant contributes 10-15 percent of the US sales (Rs 964 crore in FY16).

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.


Wockhardt Share Price

1406.45 -51.10 (-3.51%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×